Introduction to diabetes mellitus

Traditional Medicines for Modern Times: Antidiabetic Plants

Volumn , Issue , 2005, Pages 1-17

  Baynes, Kevin C R ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79952331136     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1201/9781420019001     Document Type: Chapter

References (85)

1. Tattersall, R.B., The history of diabetes mellitus, in Textbook of Diabetes, 3rd ed., Pickup, J.C. and Williams, G. Blackwell Science, Oxford, 2003, 1.1-1.22.
2. Bonadonna, R.C. et al., Dose-dependent effect of insulin on plasma free fatty acid turnover and oxidation in humans, Am. J. Physiol. 259, E736-E750, 1990.
3. Moller-Loswick, A.C. et al., Insulin selectively attenuates breakdown of nonmyofibrillar proteins in peripheral tissues of normal men, Am. J. Physiol. 29, E645-E652, 1994.
4. Louard, R.J. et al., Insulin sensitivity of protein and glucose metabolism in human forearm skeletal muscle, J. Clin. Invest. 90, 2348-2354, 1992.
5. Cherrington, A.D., Control of glucose uptake and release by the liver in vivo, Diabetes 48, 1198-1214, 1999.
6. Jiang, G. and Zhang, B.B., Glucagon and regulation of glucose metabolism, Am. J. Physiol. 284, E671-E678, 2003.
7. Saltiel, A.R. and Kahn, C.R., Insulin signaling and the regulation of glucose and lipid metabolism, Nature 414, 799-806, 2001.
8. White, M.F. and Kahn, C.R., The insulin signaling system, J. Biological Chem. 269(1), 1-4, 1994.
9. Barrett, E.J., Insulin’s effect on glucose production: direct or indirect? J. Clin. Invest. 111(4), 434-435, 2004.
10. Boden, G. et al., FFA cause hepatic insulin resistance by inhibiting insulin suppression of glycogenolysis, Am. J. Physiol. 283, E12-E19, 2002.
11. Keller, S.R. and Lienhard, G.E., Insulin signalling: the role of insulin receptor substrate 1, Trends Cell Biol. 4, 115-119, 1994.
12. Shepherd, P.R., Withers, D.J., and Siddle, K., Phosphoinositide 3-kinase: the key switch mechanism in insulin signalling, Biochem. J. 333(Pt3), 471-490, 1998.
13. Bryant, N.J., Govers, R., and James, D.E., Regulated transport of the glucose transporter GLUT4, Nat. Rev.: Molecular Cellular Biol. 3, 267-277, 2002.
14. Shepherd, P.R. and Kahn, B.B., Glucose transporters and insulin action, N. Engl. J. Med. 341, 248-257, 1999.
15. World Health Organization, Definition, diagnosis and classification of diabetes mellitus and its complications - part 1: diagnosis and classification of diabetes mellitus, WHO, Geneva, 1999.
16. Petrovsky, N. and Schatz, D.A., The immunology of human type 1 diabetes, in Textbook of Diabetes, 3rd ed., Pickup, J.C. and Williams, G. Blackwell Science, Oxford, 2003, 18.11-18.14.
17. Kelly, M.A., Mijovic, C.H., and Barnett, A.H., Genetics of type 1 diabetes, Best Prac. Res. Clin. Endocrinol. Metab. 15(3), 279-291, 2001.
18. Concannon, P. et al., A second-generation screen of the human genome for susceptibility to insulindependent diabetes mellitus, Nat. Genet. 19, 292-296, 1998.
19. Cox, N.J. et al., Seven regions of the genome show evidence of linkage to type 1 diabetes in a consensus analysis of 767 multiplex families, Am. J. Hum. Genet. 69, 820-830, 2001.
20. Davies, J.L. et al., A genome-wide search for human type-1 diabetes susceptibility genes, Nature 371(6493), 130-136, 1994.
21. Mein, C.A. et al., A search for type 1 diabetes susceptibility genes in families from the United Kingdom, Nat. Genet. 19, 297-300, 1998.
22. Krentz, A.J., Insulin Resistance, Blackwell Science, Oxford, 2002.
23. Mahler, R.J. and Adler, M.L., Type 2 diabetes mellitus: update on diagnosis, pathophysiology, and treatment, J. Clin. Endocrinol. Metab. 84(4), 1165-1171, 1999.
24. Reaven, G.M., Role of insulin resistance in human disease, Diabetes 37(12), 1595-1607, 1988.
25. Yalow, R.S. and Berson, S.A., Plasma insulin concentrations in nondiabetic and early diabetic subjects: determinations by a new sensitive immunoassay technique, Diabetes 9, 254-260, 1960.
26. Ferrannini, E. et al., Predominant role of reduced beta-cell sensitivity to glucose over insulin resistance in impaired glucose tolerance, Diabetologia 46, 1211-1219, 2003.
27. Pratley, R.E. and Weyer, C., The role of impaired early insulin secretion in the pathogenesis of Type II diabetes mellitus, Diabetologia 44, 929-945, 2001.
28. U.K. Prospective Diabetes Study Group, U.K. Prospective Diabetes Study 16. Overview of 6 years’ therapy of type II diabetes: a progressive disease, Diabetes 44, 1249-1258, 1995.
29. O’Rahilly, S., Turner, R., and Matthews, D., Impaired pulsatile secretion of insulin in relatives of patients with noninsulin-dependent diabetes, N. Engl. J. Med. 318, 1225-1230, 1988.
30. Yamagata, K. et al., Mutations in the hepatocyte nuclear factor-4 alpha gene in maturity-onset diabetes of the young (MODY1), Nature 384, 458-460, 1996.
31. Horikawa, Y. et al., Mutation in hepatocyte nuclear factor-1 beta gene (TCF2) associated with MODY, Nat. Genet. 17(4), 384-385, 1997.
32. Stoffel, M. et al., Missense glucokinase mutation in maturity-onset diabetes of the young and mutation screening in late-onset diabetes, Nat. Genet. 2, 153-156, 1992.
33. Stoffers, D.A. et al., Early-onset type-II diabetes mellitus (MODY4) linked to IPF1, Nat. Genet. 17(2), 138-139, 1997.
34. Vionnet, N. et al., Nonsense mutation in the glucokinase gene causes early-onset non-insulin-dependent diabetes mellitus, Nature 356, 721-722, 1992.
35. Yamagata, K. et al., Mutations in the hepatocyte nuclear factor-1 alpha gene in maturity-onset diabetes of the young (MODY3), Nature 384, 455-458, 1996.
36. Horikawa, Y., Oda, N., and Cox, N.J., Genetic variation in the gene encoding calpain-10 is associated with type 2 diabetes mellitus, Nat. Genet. 26, 163-175, 2000.
37. Hu, F.B. et al., Diet, lifestyle, and the risk of type 2 diabetes mellitus in women, N. Engl. J. Med. 345, 790-797, 2001.
38. Bokyo, E.J. et al., Visceral adiposity and risk of type 2 diabetes, Diabetes Care 23(4), 465-471, 2000.
39. McGarry, J.D. and Dobbins, R.L., Fatty acids, lipotoxicity and insulin secretion, Diabetologia 42, 128-138, 1999.
40. Hales, C.N. and Barker, D.J.P., Type-2 (non-insulin-dependent) diabetes mellitus - the thrifty phenotype hypothesis, Diabetologia 35(7), 595-601, 1992.
41. Hales, C.N. et al., Fetal and infant growth and impaired glucose tolerance at age 64, Br. Med. J. 303(6809), 1019-1022, 1991.
42. Ozanne, S.E. et al., Poor fetal nutrition causes long-term changes in expression of insulin signaling components in adipocytes, Am. J. Physiol.-Endocrinol. Metab. 36(1), E46-E51, 1997.
43. Onkamo, P. et al., Worldwide increase in incidence of type I diabetes - the analysis of the data on published incidence trends, Diabetologia 42, 1395-1403, 1999.
44. Gale, E.A.M. and Gillespie, K.M., Diabetes and gender, Diabetologia 44, 3-15, 2001.
45. DeFronzo, R.A., The triumvirate - β-cell, muscle, liver. A collusion responsible for NIDDM, Diabetes 37(6), 667-687, 1988.
46. U.K. Prospective Diabetes Study Group, Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33), Lancet 352, 837-853, 1998.
47. Harris, M.I. et al., Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey, 1988-1994, Diabetes Care 21, 518-524, 1998.
48. Kannel, W.B. and McGee, D.L., Diabetes and glucose tolerance as risk factors for cardiovascular disease: the Framingham Study, Diabetes Care 2, 120-126, 1979.
49. Haffner, S.M. et al., Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction, N. Engl. J. Med. 339, 229-234, 1998.
50. Lehto, S. et al., Predictors of stroke in middle-aged patients with non-insulin-dependent diabetes, Stroke 27, 63-68, 1996.
51. Chaturvedi, N. et al., Risk factors, ethnic differences and mortality associated with lower-extremity gangrene and amputation in diabetes. The WHO multinational study of vascular disease in diabetes, Diabetologia 44, S65-S71, 2001.
52. Amos, A.F., McCarty, D.J., and Zimmet, P., The rising global burden of diabetes and its complications: estimates and projections to the year 2010, Diabetic Med. 14, S7-S85, 1997.
53. Mokdad, A.H. et al., Diabetes trends in the U.S.: 1990-1998, Diabetes Care 23, 1278-1283, 2000.
54. Wild, S. et al., Global prevalence of diabetes: estimates for the year 2000 and projections for 2030, Diabetes Care 27, 1047-1053, 2004.
55. Diabetes Control and Complications Trial Research Group, The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus, N. Engl. J. Med. 329, 977-986, 1993.
56. Fuller, J.H. et al., Risk factors for cardiovascular mortality and morbidity: The WHO multinational study of vascular disease in diabetes, Diabetologia 44, S54-S64, 2001.
57. Stratton, I.M. et al., Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study, Br. Med. J. 321, 405-412, 2000.
58. U.K. Prospective Diabetes Study Group, Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34), Lancet 352, 854-865, 1998.
59. Nakagami, T. and DECODA Study Group, Hyperglycaemia and mortality from all causes and from cardiovascular disease in five populations of Asian origin, Diabetologia 47, 385-394, 2004.
60. Nauck, M.A. et al., Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans, Am. J. Physiol.-Endocrinol. Metab. 36(5), E981-E988, 1997.
61. Wynne, K., Stanley, S., and Bloom, S., The gut and regulation of body weight, J. Clin. Endocrinol. Metab. 89, 2576-2582, 2004.
62. Groop, P.H. et al., Long-term effects of guar gum in subjects with non-insulin dependent diabetes mellitus, Am. J. Clin. Nutr. 58, 513-518, 1993.
63. Coniff, R. et al., Reduction of glycosylated hemoglobin and postprandial hyperglycemia by acarbose in patients with NIDDM, Diabetes Care 18, 817-824, 1995.
64. Ashcroft, F.M. and Gribble, F.M., ATP-sensitive K+ channels and insulin secretion: their role in health and disease, Diabetologia 42, 903-919, 1999.
65. Perry, T. and Greig, N.H., The glucagon-like peptides: a double-edged therapeutic sword? Trends Pharm. Sci. 24, 377-383, 2003.
66. Harder, H., Nielson, L., and Astrup, A., The effect of liraglutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 24-h energy expenditure in patients with type 2 diabetes, Diabetes Care 27, 1915-1921, 2004.
67. Madsbad, S. et al., Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial, Diabetes Care 27, 1335-1342, 2004.
68. Bolli, G.B. et al., Insulin analogues and their potential in the management of diabetes mellitus, Diabetologia 42, 1151-1167, 1999.
69. Sachs, D.H. and Bonner-Weir, S., New islets from old, Nat. Med. 6, 250-251, 2000.
70. White, S.A. et al., Human islet cell transplantation - future prospects, Diabetic Med. 18, 78-103, 2001.
71. Flier, J.S., Big deal about a little insulin, Nat. Med. 5, 614-615, 1999.
72. Martin, W.H. et al., Discovery of a human liver glycogen phosphorylase inhibitor that lowers blood glucose in vivo, Proc. Natl. Acad. Sci. USA 95(4), 1776-1781, 1998.
73. Nolan, J.J. et al., Rosiglitazone once daily provides effective glycaemic control in patients with type 2 diabetes mellitus, Diabetic Med. 17, 287-294, 2000.
74. Tan, M.H., How pioglitazone affects glucose and lipid metabolism, Exp. Clin. Endocrinol. Diabetes 108, S224-S233, 2000.
75. Moller, D.E., New drug targets for type 2 diabetes and the metabolic syndrome, Nature 141, 821-827, 2001.
76. Boden, G., Role of fatty acids in the pathogenesis of insulin resistance and NIDDM, Diabetes 46(1), 3-10, 1997.
77. Duncan, G.E. et al., Exercise training, without weight loss, increases insulin sensitivity and postheparin plasma lipase activity in previously sedentary adults, Diabetes Care 26, 557-562, 2003.
78. Thomas, E.L. et al., Preferential loss of visceral fat following aerobic exercise, measured by magnetic resonance imaging, Lipids 35, 769-776, 2000.
79. Winder, W.W. and Hardie, D.G., AMP-activated protein kinase, a metabolic master switch: possible roles in type 2 diabetes, Am. J. Physiol. 40, E1-E10, 1999.
80. Zierath, J.R., Krook, A., and Wallberg-Henriksson, H., Insulin action and insulin resistance in human skeletal muscle, Diabetologia 43, 821-835, 2000.
81. Diabetes Prevention Program Research Group, Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin, N. Engl. J. Med. 346, 393-403, 2002.
82. Pan, X.R. et al., Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance: the Da Qing IGT and diabetes study, Diabetes Care 20, 537-544, 1997.
83. Tuomilehto, J. et al., Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance, N. Engl. J. Med. 344, 1343-1350, 2001.
84. Thornalley, P.J., Cell activation by glycated proteins. AGE receptors, receptor recognition factors and functional classification of AGEs, Cellular Molecular Biol. 44, 1013-1023, 1998.
85. Beisswenger, P.J. et al., Alpha-oxoaldehyde metabolism and diabetic complications, Biochem. Soc. Trans. 31, 1358-1363, 2003.